Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nanjing Leads Biolabs CoHKSE:09887 +8.04%10 Quick Ratio is 3.25 as of Dec. 2025, which is 117% above its 10-year median of 1.50. GuruFocus rates HKSE:09887 with a GF Score™ of 10/100. The stock has 1 warning sign investors should review. Among 1,411 Biotechnology companies, Nanjing Leads Biolabs Co ranks worse than 53.08% on this metric.
Nanjing Leads Biolabs Co (HKSE:09887) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Nanjing Leads Biolabs Co Quick Ratio Related Terms
Nanjing Leads Biolabs Co Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Leads Biolabs Co Quick Ratio Chart
Nanjing Leads Biolabs Co Annual Data
Trend
Dec23
Dec24
Dec25
Quick Ratio
0.26
1.50
3.25
Nanjing Leads Biolabs Co Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Quick Ratio
0.26
0.00
1.50
1.01
3.25
HKSE:09887 vs VRTX, REGN, RVMD: Quick Ratio Comparison
For the Biotechnology subindustry, Nanjing Leads Biolabs Co's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanjing Leads Biolabs Co Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanjing Leads Biolabs Co's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Nanjing Leads Biolabs Co's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Nanjing Leads Biolabs Co's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Leads Biolabs Co (HKSE:09887) has a Quick Ratio of 3.25 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Nanjing Leads Biolabs Co and its competitors. This is 117% above median its historical median of 1.50. Over the past decade, Nanjing Leads Biolabs Co's Quick Ratio has ranged from 0.26 to 3.25. According to the industry distribution chart, Nanjing Leads Biolabs Co ranks #749 out of 1411 companies in the Biotechnology industry, placing it in the top 53.1%.
Is Nanjing Leads Biolabs Co's Quick Ratio too high?
Nanjing Leads Biolabs Co's current Quick Ratio of 3.25 is 117% above median its 10-year median of 1.50. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 3.25. The Biotechnology industry median Quick Ratio is 3.65. Nanjing Leads Biolabs Co's value of 3.25 is 11% below this industry median. Based on the distribution chart, Nanjing Leads Biolabs Co ranks #749 out of 1411 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Nanjing Leads Biolabs Co has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Nanjing Leads Biolabs Co's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanjing Leads Biolabs Co ranks #749 out of 1411 companies for Quick Ratio. This places Nanjing Leads Biolabs Co in the lower half of its industry. The industry median Quick Ratio is 3.65. Nanjing Leads Biolabs Co's value of 3.25 is 11% below this benchmark. Historically, Nanjing Leads Biolabs Co's own Quick Ratio has ranged from 0.26 to 3.25 over the past decade. While the company's 10-year median is 1.50 vs. the industry median of 3.65, Nanjing Leads Biolabs Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.65, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanjing Leads Biolabs Co's current Quick Ratio of 3.25 is 11% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Nanjing Leads Biolabs Co and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanjing Leads Biolabs Co's current Quick Ratio is 3.25, which is 117% above median its own 10-year median of 1.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Leads Biolabs Co stock overvalued right now?
Nanjing Leads Biolabs Co (HKSE:09887) has a current Quick Ratio of 3.25. The current Quick Ratio is 3.25, which is 117% above median its 10-year median of 1.50 and 11% below the Biotechnology industry median of 3.65. Nanjing Leads Biolabs Co's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Nanjing Leads Biolabs Co (HKSE:09887), the current Quick Ratio is 3.25 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nanjing Leads Biolabs Co Ltd is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. The Group uses its science-driven R&D approach and three proprietary technology platforms: X-body (4-1BB Engager), LeadsBody (CD3 T Cell Engager), and TOPiKinectics (ADC), for its multi-modal, differentiated pipeline in oncology and autoimmune diseases. It has approximately fourteen drug candidates across oncology and autoimmune diseases. Among these, one core product (LBL-024, a pivotal-stage PD-L1 and 4-1BB dual-targeting bispecific antibody) is being evaluated in several cancer indications and across various Proof-of-Concept (POC) studies. The Group generates maximum revenue from the USA.
10GF Score
Get the complete analysis for HKSE:09887
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09887 has been successfully added to your 
